Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04440436 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 8, 2020 (before its estimated June 4, 2022 completion). Its status may not reflect the trial's current state.

Record History

  1. Collaborators expanded, about 5 wordsv2 See this version in full on ClinicalTrials.gov ↗
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a phase I/II, multicenter study to assess the efficacy and safety of IM19 CAR-T cells in adult with R/R Non-Hodgkins Lymphoma in China.
Trial Details
NCT Number NCT04440436
Lead Sponsor Beijing Immunochina Medical Science & Technology Co., Ltd.
Collaborators: Jiangsu Simcere Pharmaceutical Co., Ltd.
Conditions NHL
Enrollment 52 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov